Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer



Status:Completed
Conditions:Prostate Cancer, Cancer, Erectile Dysfunction
Therapuetic Areas:Nephrology / Urology, Oncology
Healthy:No
Age Range:40 - 65
Updated:4/2/2016
Start Date:July 2009
End Date:January 2013
Contact:Alison Champagne, BS
Email:achampa@harthosp.org
Phone:860-545-6049

Use our guide to learn which trials are right for you!

Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy

The purpose of this study is to determine if adding hyperbaric oxygen therapy, a therapy
that delivers oxygen under slight pressure, to a drug treatment of PDE5I (such as Viagra,
Levitra, Cialis)for men following surgery for prostate cancer will result in more men being
able to continue to have erections.

Prostate cancer is the most common non-skin malignancy in men in the United States, with
approximately 232,000 diagnoses of adenocarcinoma projected for 2005. More than 150,000 of
these men are treated with radical prostatectomy. Common sequelae following successful NSRRP
(nerve-sparing radical retropubic prostatectomy)include urinary incontinence and sexual
dysfunction. Recent advances in surgery technique and treatment have been made but in spite
of aggressive management, recovery of sexual function is incomplete with fewer than
one-fifth reporting return to baseline. The etiology of erectile dysfunction following
radical prostatectomy results most probably from local surgical trauma and neurapraxia,
which leads to corpus cavernosal hypoxemia in the post-NSRRP period. This hypoxemia is
believed to impact negatively on the health and maintenance of the smooth muscle cells
within the corpus cavernosum. Hyperbaric oxygen therapy (HBO2T) is a unique modality that is
able to provide oxygen delivery to tissues that have been damaged by traumatic injury.

Hypothesis: The addition of post-NSRRP hyperbaric oxygen therapy (HBO2T) to a treatment of
phosphodiesterase type 5 inhibitor (PDE5I) will reduce the incidence of erectile dysfunction
(ED) and urinary incontinence when measured at 1, 3, 6, 12 and 18 months post-NSRRP for
Stage I prostate cancer.

Inclusion Criteria:

- male

- age 40-69

- diagnosis of Stage I prostate cancer

- bilateral NSRRP as primary treatment

- sexual potency prior to surgery

Exclusion Criteria:

- COPD, CHF, diabetes mellitus

- known inability to tolerate PDE5I

- confinement anxiety/claustrophobia

- planned adjuvant or neo-adjuvant therapy

- patients taking alpha blockers or nitrates

- patients with retinitis pigmentosa
We found this trial at
1
site
80 Seymour St
Hartford, Connecticut 6102
(860) 545-5000
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
?
mi
from
Hartford, CT
Click here to add this to my saved trials